Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation
mRNA translation modulators -
a novel target space
Tremendous opportunities - unique advantages
novel target space
Our platform identifies small molecules that selectively modulate the mRNA translation of target proteins. The novel target space enables the discovery of drugs that can either decrease or increase the production of proteins in a tissue selective manner.
Specifically decrease or increase the mRNA translation of target proteins
Tissues use different regulatory proteins for the same mRNA allowing for selective Translation Control
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington’s Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions).
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact email@example.com.
17 Scientific Collaborations
Eur J Cell Biol (2018) ; 97 : 168-179.
Integr Biol (2016); 8 :645-53
J Cell Biol. 2016; 23;213(4):451-62.
Nucleic Acid Res. (2017); 45 :926-937
News & Events
13th Annual European Life Sciences CEO Forum
When: Feb. 19th, 2020 - Feb. 20th, 2020
Where: Zurich, Switzerland
Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 13th Annual European Life Sciences CEO Forum.
The conference serves as a global biopharma industry forum that addresses the main challenges for 2020 investment, partnering and alliance management. Key players contribute their insights via panels, which cover the macro picture and innovation in different therapeutic sectors. The forum also features keynote speeches by KOLs and approximately 60 corporate presentations from established public and private emerging biotech companies.
2020 BIO CEO & Investor Conference
When: Feb. 10th, 2020 - Feb. 11th, 2020
Where: New York, USA
Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2020 BIO CEO & Investor Conference.
Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private companies. The conference prides itself on showcasing the best of biotech with two days of productive partnering meetings with institutional and early-stage investors, industry analysts and senior biotechnology executives.
6th Annual LSX World Congress
When: Feb. 4th, 2020 - Feb. 5th, 2020
Where: London, UK
Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 6thAnnual LSX World Congress. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will also participate with other experts as part of the “Platforms and Partnerships” panel.
For five years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science business strategy, investment, partnering, deal-making, and commercialization. The LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life science giants and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.